课题基金 / 基金详情

Development of a Novel, Safe Method for the Non-invasive Assessment of Human Bone Quality, In Vivo, using spatially offset Raman spectroscopy.

Development of a Novel, Safe Method for the Non-invasive Assessment of Human Bone Quality, In Vivo, using spatially offset Raman spectroscopy.
使用空间偏移拉曼光谱开发一种新颖、安全的体内人体骨骼质量非侵入性评估方法。
批准号:
EP/H002693/1
负责人:
Allen Goodship
金额:
$212.59万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2010
资助国家:
英国
项目状态:
已结题
起止时间:
2010 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The proposed activity is part of an exciting programme of international and multi-disciplinary work developing Raman spectroscopy of skeletal tissues for clinical use; measured for the first time through the unbroken skin. We are initially targeting bone in patients with osteoporosis, but this novel technology is applicable to other tissues and conditions. This project will add value to our work with three major associated developments: optimisation of bone spectroscopy through skin (both temporally and spatially-resolved techniques); identification of major spectral features that are associated with bone strength; and improving fracture risk predictions in comparison to the current standard DXA scans. A major problem our Society faces as a consequence of continual advances in healthcare and increasing wealth is enhanced life expectancy. With this the ability to enjoy a healthy and active ageing is often compromised by painful long lasting degenerative diseases of the musculoskeletal system. Indeed the Government is keen on prevention through ealry diagnosis and lifestyle changes, health ageing is a National Government priority.Current techniques used to identify the major degenerative skeletal diseases such as osteoarthritis and osteoporosis are based on imaging using X-ray radiation (DXA scanning, CT scans and Radiography). These technologies are limited as they rely on imaging the mineral component of the bone tissue, the mechanical strength of bone,however, is determined largely by the protein component, predominantly collagen type I and this is invisible to X-ray techniques.Bone tissue is a composite material comprising an inorganic mineral crystal component and an organic proteinaceous fibre component. The mineral fraction largley determines the stiffness of the material and the fibre component the strength.Many bone diseases and age related changes to the skeleton arise as a consequence of changes in the protein chemistry, either as a consequence of the genetic make up of an indivudual or the mechanical loading of the bone itself.Recently our collaborative team has developed a new revolutionary technique capable of determining bone tissue composition non-invasively through patients' skin. The concept, Spatially Offset Raman Spectroscopy (SORS), enables safe characterisation of tissue in vivo at depths of several millimetres. This is by at least an order of magnitude deeper than that possible with conventional Raman methods. Our breakthrough paves the way for the development of safe techniques for the early diagnosis of diseases where subtle molecular details within tissue can provide indicators of health problems, for example, the non-invasive diagnosis of genetic bone disease such as brittle bone disease and degenerative conditions such as arthritis. Other analytical applications include the probing of pharmaceutical products in depth and through coatings and packaging, the subsurface probing of paints, food products and security screening. The research project is enhanced through a strong cross-disciplinary science component opening a new branch of Raman spectroscopy with strong potential for commercial exploitation of research outcomes. Our research has permitted us to obtain the first Raman spectra of human bone in vivo under totally safe conditions (2 mW) as a basic proof of concept. Although as yet unoptimised the available information can be contrasted with that obtainable using conventional X-ray techniques such as DEXA which only yield the density of the mineral component. The extra information contained in Raman spectra holds promise for the characterisation of bone diseases such as osteoporosis or brittle bone disease. To realise this goal, further research is now needed to increase the penetration depth and establish a firm link between Raman spectra and specific bone diseases. This proposal has the potential to develop a new diagnostic modality in modern medicine.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1007/s00198-016-3846-6
发表时间: 2017-03
期刊: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
影响因子: --
作者: [Bergström I, Kerns JG, Törnqvist AE, Perdikouri C, Mathavan N, Koskela A, Henriksson HB, Tuukkanen J, Andersson G, Isaksson H, Goodship AE, Windahl SH]
通讯作者: Windahl SH
Osteoporosis: bouncing babies to crumbling wrinklies- the need to own our bones
骨质疏松症:婴儿弹跳到皱纹不断——需要拥有我们的骨头
DOI: --
发表时间:
期刊:
影响因子: --
作者: [Allen Goodship (Author)]
通讯作者: Allen Goodship (Author)
DOI: 10.1007/s00198-018-4496-7
发表时间: 2018-09
期刊: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
影响因子: --
作者: [Bergström I, Kerns JG, Törnqvist AE, Perdikouri C, Mathavan N, Koskela A, Henriksson HB, Tuukkanen J, Andersson G, Isaksson H, Goodship AE, Windahl SH]
通讯作者: Windahl SH
DOI: 10.1002/jrs.4038
发表时间: 2012-09-01
期刊: JOURNAL OF RAMAN SPECTROSCOPY
影响因子: 2.5
作者: [Buckley, Kevin, Matousek, Pavel, Goodship, Allen E.]
通讯作者: Goodship, Allen E.
国内基金
海外基金
Novel-miR-1134调控LHCGR的表达介导拟 穴青蟹卵巢发育的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2025
  • 负责人:
    崔文晓
  • 依托单位:
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
  • 批准号:
    82304677
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30.00万元
  • 批准年份:
    2023
  • 负责人:
    边兴博
  • 依托单位:
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
  • 批准号:
    82304658
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    刘亚
  • 依托单位:
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
  • 批准号:
    32102747
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.0万元
  • 批准年份:
    2021
  • 负责人:
    李婉雁
  • 依托单位: